JMKX001899 + rifampin

**JMKX001899 + rifampin** is a combination regimen consisting of JMKX001899, an orally administered, irreversible and selective small molecule inhibitor of KRAS G12C, and rifampin, a well-established rifamycin-class antibiotic most commonly used in the treatment of tuberculosis. JMKX001899 acts by locking the KRAS G12C mutant protein in its inactive GDP-bound state, thereby inhibiting oncogenic signaling responsible for cancer cell proliferation, especially in non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation[1][7]. Rifampin is a potent inducer of cytochrome P450 enzymes and is sometimes used in clinical pharmacology studies as a standard agent to examine drug–drug interaction potential, especially via its effects on hepatic enzyme induction. This combination may be used specifically in drug–drug interaction studies to evaluate the metabolic effects of rifampin on the pharmacokinetics and safety of JMKX001899[7].

Other names

JMKX001899JMKX-001899JMKX 001899rifampicin